Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

The safety profile of interleukin (IL) inhibitors is not well established.

Objective

To assess the risk of serious infections, opportunistic infections, and cancer in patients with rheumatologic diseases treated with IL inhibitors.

Data sources

Ovid MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations; Ovid MEDLINE Daily; Ovid Embase; Ovid Cochrane Central Register of Controlled Trials; Ovid Cochrane Database of Systematic Reviews; and Scopus were searched (inception to November 30, 2018).

Study selection

Randomized, placebo-controlled trials that evaluated IL inhibitor therapies in rheumatic diseases and reported safety data were included in the analyses.

Data extraction and synthesis

This systematic review is reported ac

SUBMITTER: Bilal J 

PROVIDER: S-EPMC6813598 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature